DrugPatentWatch Database Preview
GLYCOPYRROLATE Drug Profile
Try a free trial
See Plans and Pricing
When do Glycopyrrolate patents expire, and what generic alternatives are available?
Glycopyrrolate is a drug marketed by Abraxis Pharm, Amneal Pharms Co, Aurobindo Pharma Ltd, Caplin, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Luitpold, Piramal Critical, Prinston Inc, Sandoz Inc, Somerset Theraps Llc, Teva Parenteral, Watson Labs, Aurolife Pharma Llc, Dr Reddys Labs Ltd, Heritage Pharms Inc, Hikma Intl Pharms, Kenton, Leading Pharma Llc, Natco Pharma Ltd, Nexgen Pharma, Orit Labs Llc, Oxford Pharms, Par Pharm, Renata, Rising, and Sun Pharm Inds Ltd. and is included in thirty-four NDAs.
The generic ingredient in GLYCOPYRROLATE is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for GLYCOPYRROLATE
Pharmacology for GLYCOPYRROLATE
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
Medical Subject Heading (MeSH) Categories for GLYCOPYRROLATE
Synonyms for GLYCOPYRROLATE
| .beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide |
| (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenyl-acetate bromide |
| (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide |
| [(3S)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide |
| 1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide |
| 1-methyl-3-pyrrolidyl alpha-cyclopentylmandelate methobromide |
| 1-methyl-3-pyrrolidyl alpha-phenyl-alpha-cyclopentylglycolate methobromide |
| 1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide |
| 1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate |
| 1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate |
| 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-ium bromide |
| 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium Bromide |
| 3-(2-phenyl-2-cyclopentylglycoloyloxy)-1,1-dimethylpyrrolidinium bromide |
| 3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid |
| 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium bromide |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate |
| 475468-09-8 |
| 51186-83-5 |
| 53808-86-9 |
| 596-51-0 |
| AB0010706 |
| AC-23382 |
| AC1L1XX0 |
| AC1LAW54 |
| AC1Q1RGS |
| AD-237 |
| AHR 504 |
| AHR-504 |
| AKOS015962136 |
| alpha-cyclopentylmandelic acid ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide |
| AN-46262 |
| Asecryl |
| BC209826 |
| BCP07110 |
| Bromure de glycopyrronium |
| Bromure de glycopyrronium [INN-French] |
| Bromure de ritropirronio |
| Bromure de ritropirronium |
| Bromuro de glicopirronio |
| Bromuro de glicopirronio [INN-Spanish] |
| C19H28BrNO3 |
| C19H28NO3 |
| CAS-596-51-0 |
| CCG-101030 |
| CCG-213543 |
| CHEBI:90972 |
| CHEMBL1201027 |
| CHF-5992 |
| Copyrrolate |
| CPD000469282 |
| CS-1763 |
| Cuvposa |
| Cuvposa (TN) |
| D00540 |
| DSSTox_CID_3109 |
| DSSTox_GSID_23109 |
| DSSTox_RID_76878 |
| DTXSID6023109 |
| EINECS 209-887-0 |
| erythro-3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate |
| erythro-3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate. |
| FT-0626787 |
| G0392 |
| Gastrodyn |
| Glycopyrrolate (USP) |
| Glycopyrrolate [USAN:USP] |
| Glycopyrrolate [USAN] |
| Glycopyrrolate bromide |
| Glycopyrrolate, >=98% (HPLC) |
| Glycopyrrolate, United States Pharmacopeia (USP) Reference Standard |
| GLYCOPYRRONE BROMIDE |
| Glycopyrroni bromidum |
| Glycopyrronii bromidum |
| Glycopyrronii bromidum [INN-Latin] |
| Glycopyrronium |
| glycopyrronium bromide |
| Glycopyrronium Bromide ,(S) |
| Glycopyrronium bromide (JAN/INN) |
| Glycopyrronium bromide, European Pharmacopoeia (EP) Reference Standard |
| Glycopyrronium for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Glycopyrronium impurity N, European Pharmacopoeia (EP) Reference Standard |
| HMS1570E14 |
| HMS2051P12 |
| HMS2094A05 |
| HMS2097E14 |
| HMS2235F12 |
| HMS3259P04 |
| HMS3369F10 |
| HMS3393P12 |
| HMS3714E14 |
| HY-17465 |
| I14-3643 |
| Lonhala Magnair |
| LS-138344 |
| Mandelic acid, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide |
| MFCD00072137 |
| MLS001424112 |
| MLS002222301 |
| MolPort-006-112-011 |
| NC00280 |
| NC00694 |
| NCGC00179456-02 |
| NCGC00179456-04 |
| Nodapton |
| Nodapton|||Robanul|||Robinul|||Tarodyl|||Tarodyn |
| NSC 250836 |
| NSC 251251 |
| NSC 251252 |
| NSC-250836 |
| NSC-251251 |
| NSC-251252 |
| NSC-759238 |
| NSC250836 |
| NSC251251 |
| NSC251252 |
| NSC759238 |
| NVA 237 |
| NVA-237 |
| OR315526 |
| Pharmakon1600-01505753 |
| PT-001 |
| Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate |
| Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide |
| Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate |
| Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI) |
| Pyrrolidinium,1-dimethyl-, bromide |
| Pyrrolidinium,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate |
| Ritropirronium bromide |
| Ritropirronium bromide [INN] |
| RL04249 |
| Robanul |
| Robinal |
| Robinul |
| Robinul (TN) |
| ROBINUL FORTE |
| s4660 |
| SAM001246629 |
| SAM002589987 |
| SCHEMBL41436 |
| Seebri |
| Seebri Breezhaler |
| Seebri breezhaler (TN) |
| Seebri Neohaler |
| SMR000469282 |
| SR-01000763650 |
| SR-01000763650-3 |
| ST24047338 |
| Tarodyl |
| Tarodyn |
| Tox21_113144 |
| Tox21_113144_1 |
| Tox21_113145 |
| VPNYRYCIDCJBOM-UHFFFAOYSA-M |
| WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E |
US Patents and Regulatory Information for GLYCOPYRROLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Ltd | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 040844-001 | Aug 18, 2009 | AA | RX | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | |||
| Orit Labs Llc | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 203657-002 | Nov 30, 2018 | AA | RX | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | |||
| Watson Labs | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 085563-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | ||||
| Natco Pharma Ltd | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 091413-001 | Jun 20, 2016 | AA | RX | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | |||
| Oxford Pharms | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 090020-001 | Oct 19, 2011 | AA | RX | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | |||
| Natco Pharma Ltd | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 091413-002 | Jun 20, 2016 | AA | RX | No | No | Try a Free Trial | Try a Free Trial | Try a Free Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
